These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20567105)

  • 1. [Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].
    Nitta T; Yamasaki M; Kajihara T; Mito A; Awaya H; Ikegami Y; Arita K
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1045-9. PubMed ID: 20567105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
    Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
    Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
    Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
    Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
    Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
    Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
    J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Our clinical experiences of amrubicin hydrochloride monotherapy in extensive-disease small cell lung cancer].
    Kawakami M; Ohno S; Tsujita A; Hosono T; Kobayashi A; Yamasawa H; Bando M; Sugiyama Y
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):273-6. PubMed ID: 18281764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy.
    Asai N; Ohkuni Y; Matsunuma R; Nakashima K; Iwasaki T; Kaneko N
    J Cancer Res Ther; 2012; 8(2):266-71. PubMed ID: 22842373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
    Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
    Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
    Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
    Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
    J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
    Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
    Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.
    Eckardt JR; Bentsion DL; Lipatov ON; Polyakov IS; Mackintosh FR; Karlin DA; Baker GS; Breitz HB
    J Clin Oncol; 2009 Apr; 27(12):2046-51. PubMed ID: 19289620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens.
    Igawa S; Takahashi T; Nakamura Y; Tsuya A; Ono A; Shukuya T; Murakami H; Endo M; Yamamoto N
    Anticancer Res; 2008; 28(6B):3855-8. PubMed ID: 19192640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer.
    Igawa S; Sasaki J; Ishihara M; Otani S; Maki S; Hiyoshi Y; Kasajima M; Katono K; Takakura A; Masuda N
    Chemotherapy; 2013; 59(2):99-105. PubMed ID: 24021914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
    Asayama M; Fuse N; Yoshino T; Yano T; Tahara M; Doi T; Fujii S; Ohtsu A
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1325-30. PubMed ID: 21461890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
    Kaneda H; Okamoto I; Hayashi H; Yoshioka H; Miyazaki M; Kudoh S; Kimura T; Sugiura T; Sawa T; Takeda K; Iwamoto Y; Satouchi M; Akita K; Saito H; Goto I; Shibata K; Fukuoka M; Nakagawa K;
    J Thorac Oncol; 2010 Jan; 5(1):105-9. PubMed ID: 19884859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.